for a number of reasons, such as keeping FT Sites reliable and secure,
personalising content and ads, providing social media features and to
analyse how our Sites are used.
A new world is possible.
Let's not go back to what wasn't working anyway.
Add this topic to your myFT Digest for news straight to your inbox
US biotech takes aggressive step over cancer-screening deal fearing Brussels review will not beat deadline
Novel antitrust cases complicate efforts to tackle climate change and healthcare
Biotech group’s chief warns lives will be at risk if approval process is delayed
US genomics company takes rare step after authorities indicate they will review the deal
Competition regulator’s move on Grail purchase confirms era of bolder antitrust bodies
Illumina’s Francis De Souza says global co-operation needed to keep up with new strains
Genetic sequencing company set to take full ownership of start-up
Mooted $1.2bn deal halted after scrutiny by UK and US competition watchdogs
Separating the healthcare unit makes sense. Announcing it now does not
US stocks retreat as healthcare sector posts heaviest losses
Many experts believe a new type of drug promises to revolutionise treatment
Accurately sequencing an individual’s DNA for less than $1,000 is now possible
Google among backers for group aiming to commercialise epigenome
Chemical company under pressure from activist investor Nelson Peltz
Patent cliff has been the industry’s excuse for a decade of underperformance